4/8
10:31 am
tbph
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
4/7
12:51 pm
tbph
Theravance Biopharma (TBPH) had its price target raised by B. Riley Financial, Inc. from $14.00 to $17.00. They now have a "neutral" rating on the stock.
Low
Report
Theravance Biopharma (TBPH) had its price target raised by B. Riley Financial, Inc. from $14.00 to $17.00. They now have a "neutral" rating on the stock.
4/6
01:06 am
tbph
Medium
Report
4/2
08:48 pm
tbph
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
Medium
Report
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
4/1
09:00 am
tbph
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
Low
Report
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
3/29
01:09 am
tbph
Low
Report
3/26
09:00 am
tbph
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
Low
Report
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
3/25
06:13 pm
tbph
Theravance Biopharma (TBPH) was upgraded by
Weiss Ratings from "hold (c)" to "buy (b-)".
Low
Report
Theravance Biopharma (TBPH) was upgraded by
Weiss Ratings from "hold (c)" to "buy (b-)".
3/25
09:00 am
tbph
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
Low
Report
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
3/23
11:00 am
tbph
Theravance Biopharma (TBPH) had its price target raised by TD Cowen from $13.00 to $15.00. They now have a "hold" rating on the stock.
Low
Report
Theravance Biopharma (TBPH) had its price target raised by TD Cowen from $13.00 to $15.00. They now have a "hold" rating on the stock.
3/21
07:13 am
tbph
Theravance Biopharma (TBPH) was upgraded by Zacks Research from "hold" to "strong-buy".
Medium
Report
Theravance Biopharma (TBPH) was upgraded by Zacks Research from "hold" to "strong-buy".
3/20
08:05 am
tbph
Theravance Biopharma (TBPH) had its "buy" rating reaffirmed by BTIG Research. They now have a $21.00 price target on the stock.
Medium
Report
Theravance Biopharma (TBPH) had its "buy" rating reaffirmed by BTIG Research. They now have a $21.00 price target on the stock.
3/19
02:57 pm
tbph
Theravance Biopharma reports Q4 results [Seeking Alpha]
Low
Report
Theravance Biopharma reports Q4 results [Seeking Alpha]
3/19
09:00 am
tbph
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
Medium
Report
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
3/19
08:44 am
tbph
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/19
08:30 am
tbph
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Medium
Report
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
3/18
10:00 am
tbph
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
Low
Report
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
3/11
09:00 am
tbph
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
Neutral
Report
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
3/11
05:30 am
tbph
How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash [Yahoo! Finance]
Low
Report
How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash [Yahoo! Finance]
3/5
11:00 am
tbph
Theravance Biopharma (TBPH) was downgraded by Oppenheimer Holdings, Inc. from "outperform" to "market perform".
Low
Report
Theravance Biopharma (TBPH) was downgraded by Oppenheimer Holdings, Inc. from "outperform" to "market perform".
3/4
08:00 am
tbph
Theravance Biopharma (TBPH) had its "neutral" rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.
Low
Report
Theravance Biopharma (TBPH) had its "neutral" rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.
3/4
07:43 am
tbph
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure [Yahoo! Finance]
Low
Report
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure [Yahoo! Finance]
3/3
12:23 pm
tbph
The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself [Yahoo! Finance]
Low
Report
The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself [Yahoo! Finance]
3/3
12:16 pm
tbph
Theravance Biopharma (TBPH) had its price target lowered by BTIG Research from $40.00 to $21.00. They now have a "buy" rating on the stock.
Low
Report
Theravance Biopharma (TBPH) had its price target lowered by BTIG Research from $40.00 to $21.00. They now have a "buy" rating on the stock.
3/3
11:16 am
tbph
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review [Yahoo! Finance]
Low
Report
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review [Yahoo! Finance]